从复杂HIV治疗方案转换为每日比克替拉韦加拉那卡韦的疗效与安全性:一项随机、开放标签、多中心2期研究(ARTISTRY-1)
ARTISTRY-1研究将128例接受复杂抗逆转录病毒治疗且HIV-1 RNA<50拷贝/mL的成人随机分为比克替拉韦75mg加拉那卡韦25mg组、比克替拉韦75mg加拉那卡韦50mg组或继续复杂方案组,24周时三组HIV-1 RNA≥50拷贝/mL的例数分别为0/51、1/52和0/25,CD4细胞计数和百分比保持稳定,无因严重不良事件停药,两种剂量方案耐受性良好且安全性相似。
要点
- 转换至比克替拉韦加拉那卡韦后24周病毒学抑制维持良好。
- 两种剂量方案耐受性良好,组间安全性特征相似。
- CD4细胞计数和百分比至第24周保持稳定。
核心结论
- 这些数据支持继续评估比克替拉韦与拉那卡韦联合方案,以优化接受复杂抗逆转录病毒方案且病毒学抑制的HIV感染者的治疗。
研究设计与样本
- ARTISTRY-1是一项2/3期、操作上无缝衔接、随机、开放标签、多中心、活性对照研究(GS-US-621-6289;NCT05502341)。
- 2期部分纳入血浆HIV-1 RNA<50拷贝/mL且接受复杂抗逆转录病毒方案≥6个月的成人。
- 128例参与者随机分配至比克替拉韦75mg加拉那卡韦25mg组(n=51)、比克替拉韦75mg加拉那卡韦50mg组(n=52)或继续复杂抗逆转录病毒方案组(n=25),评估至24周的疗效和安全性。
主要发现
- 第24周时,HIV-1 RNA≥50拷贝/mL的例数在三组分别为0/51、1/52(1.9%)和0/25。
- CD4细胞计数和百分比至第24周保持稳定;CD4细胞计数自基线变化的中位数(四分位距)在三组分别为18(-39至70)、-16(-80至93)和42(-36至90)个/µL。
- 至第24周,无因严重不良事件导致的研究终止。
- 两种比克替拉韦加拉那卡韦给药方案均耐受性良好,组间安全性特征相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Complex antiretroviral therapy (ART) regimens, such as those requiring multiple tablets, several doses per day, or both, can negatively affect quality of life and treatment adherence among people with human immunodeficiency virus (HIV). METHODS: ARTISTRY-1 is a phase 2/3, operationally seamless, randomized, open-label, multicenter, active-controlled study (GS-US-621-6289; NCT05502341). Phase 2 of the study enrolled adults with plasma HIV-1 RNA <50 copies/mL receiving a complex ART regimen for ≥6 months. Efficacy and safety outcomes were evaluated after a switch to bictegravir (BIC) (75-mg) + lenacapavir (LEN) (25- or 50-mg) regimens, compared with continuing on a complex ART regimen through 24 weeks. RESULTS: Overall, 128 participants were assigned randomly to begin BIC 75 mg + LEN 25 mg (n = 51) or BIC 75 mg + LEN 50 mg (n = 52) or continue on their complex ART regimen (n = 25). At week 24, HIV-1 RNA was ≥50 copies/mL in 0 of 51, 1 of 52 (1.9%), and 0 of 25 participants in the 3 groups, respectively. CD4 cell counts and percentages remained stable through week 24; the median change from baseline in CD4 cell count (interquartile range) was 18 (-39 to 70), -16 (-80 to 93), and 42 (-36 to 90) cells/µL, respectively. There were no study discontinuations due to a serious adverse event through week 24. Both BIC + LEN dosing regimens were well tolerated, with similar safety profiles observed between groups. CONCLUSIONS: These data support the continued evaluation of the combination of BIC and LEN to optimize treatment in people with HIV and virologic suppression who are receiving complex ART regimens.
引用
- Mounzer K, Slim J, Ramgopal M, et al. Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1). Clin Infect Dis. 2025. PMID: 39589133. doi:10.1093/cid/ciae522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。